June 8, 2024Open Access

Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis

Key Points

Key points are not available for this paper at this time.

Abstract

Survodutide is a glucagon/glucagon-like peptide-1 receptor dual agonist in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). We investigated the pharmacokinetic and safety profile of survodutide in people with cirrhosis.

Read Full Paperexternally

KI fragen

Bookmark

View Full Paper

Cite This Study

Lawitz et al. (Sat,) studied this question.

synapsesocial.com/papers/68e65879b6db6435875e7d31 https://doi.org/https://doi.org/10.1016/j.jhep.2024.06.003

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis2024 · 431 citations
2Glucagon Receptor Signaling and Lipid Metabolism2019 · 206 citations
3Hospitalization costs and risk of mortality in adults with nonalcoholic steatohepatitis: Analysis of a French national hospital database2020 · 28 citations
4Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study2015 · 2,134 citations
5The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis2022 · 2,137 citations

KI fragen

Bookmark

View Full Paper